Virginia A Triant1, Todd T Brown, Hang Lee, Steven K Grinspoon. 1. Program in Nutritional Metabolism, Massachusetts General Hospital, 55 Fruit Street, Longfellow 207, Boston, Massachusetts 02114. sgrinspoon@partners.org.
Abstract
CONTEXT: Reduced bone mineral density has been demonstrated among HIV-infected patients, but fracture prevalence is unknown. OBJECTIVE: The objective of the study was to compare fracture prevalence in HIV-infected and non-HIV-infected patients. DESIGN: This was a population-based study. SETTING: The study was conducted at a large U.S. health care system. PATIENTS: A total of 8525 HIV-infected and 2,208,792 non-HIV-infected patients with at least one inpatient or outpatient encounter between October 1, 1996, and March 21, 2008, was compared. MAIN OUTCOME MEASURE: Fracture prevalence using specific International Classification of Diseases, Ninth Revision, Clinical Modification fracture codes was measured. RESULTS: The overall fracture prevalence was 2.87 vs. 1.77 patients with fractures per 100 persons in HIV-infected, compared with non-HIV-infected patients (P < 0.0001). Among females, the overall fracture prevalence was 2.49 vs. 1.72 per 100 persons in HIV-infected vs. non-HIV-infected patients (P = 0.002). HIV-infected females had a higher prevalence of vertebral (0.81 vs. 0.45; P = 0.01) and wrist (1.31 vs. 0.83; P = 0.01) fractures per 100 persons, compared with non-HIV-infected females but had a similar prevalence of hip fractures (0.47 vs. 0.56; P = 0.53). Among males, the fracture prevalence per 100 persons was higher in HIV-infected vs. non-HIV-infected patients for any fracture (3.08 vs. 1.83; P < 0.0001), vertebral fractures (1.03 vs. 0.49; P < 0.0001), hip fractures (0.79 vs. 0.45; P = 0.001), and wrist fractures (1.46 vs. 0.99; P = 0.001). Fracture prevalence was higher relative to non-HIV-infected patients among African-American and Caucasian females and Caucasian males. CONCLUSIONS: Fracture prevalence is increased in HIV-infected compared with non-HIV-infected patients.
CONTEXT: Reduced bone mineral density has been demonstrated among HIV-infectedpatients, but fracture prevalence is unknown. OBJECTIVE: The objective of the study was to compare fracture prevalence in HIV-infected and non-HIV-infectedpatients. DESIGN: This was a population-based study. SETTING: The study was conducted at a large U.S. health care system. PATIENTS: A total of 8525 HIV-infected and 2,208,792 non-HIV-infectedpatients with at least one inpatient or outpatient encounter between October 1, 1996, and March 21, 2008, was compared. MAIN OUTCOME MEASURE: Fracture prevalence using specific International Classification of Diseases, Ninth Revision, Clinical Modification fracture codes was measured. RESULTS: The overall fracture prevalence was 2.87 vs. 1.77 patients with fractures per 100 persons in HIV-infected, compared with non-HIV-infectedpatients (P < 0.0001). Among females, the overall fracture prevalence was 2.49 vs. 1.72 per 100 persons in HIV-infected vs. non-HIV-infectedpatients (P = 0.002). HIV-infected females had a higher prevalence of vertebral (0.81 vs. 0.45; P = 0.01) and wrist (1.31 vs. 0.83; P = 0.01) fractures per 100 persons, compared with non-HIV-infected females but had a similar prevalence of hip fractures (0.47 vs. 0.56; P = 0.53). Among males, the fracture prevalence per 100 persons was higher in HIV-infected vs. non-HIV-infectedpatients for any fracture (3.08 vs. 1.83; P < 0.0001), vertebral fractures (1.03 vs. 0.49; P < 0.0001), hip fractures (0.79 vs. 0.45; P = 0.001), and wrist fractures (1.46 vs. 0.99; P = 0.001). Fracture prevalence was higher relative to non-HIV-infectedpatients among African-American and Caucasian females and Caucasian males. CONCLUSIONS:Fracture prevalence is increased in HIV-infected compared with non-HIV-infectedpatients.
Authors: D Felsenberg; A J Silman; M Lunt; G Armbrecht; A A Ismail; J D Finn; W C Cockerill; D Banzer; L I Benevolenskaya; A Bhalla; J Bruges Armas; J B Cannata; C Cooper; J Dequeker; R Eastell; B Felsch; W Gowin; S Havelka; K Hoszowski; I Jajic; J Janott; O Johnell; J A Kanis; G Kragl; A Lopes Vaz; R Lorenc; G Lyritis; P Masaryk; C Matthis; T Miazgowski; G Parisi; H A P Pols; G Poor; H H Raspe; D M Reid; W Reisinger; C Schedit-Nave; J J Stepan; C J Todd; K Weber; A D Woolf; O B Yershova; J Reeve; T W O'Neill Journal: J Bone Miner Res Date: 2002-04 Impact factor: 6.741
Authors: Todd T Brown; Mary D Ruppe; Rory Kassner; Princy Kumar; Theresa Kehoe; Adrian S Dobs; Joseph Timpone Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: S Jones; D Restrepo; A Kasowitz; D Korenstein; S Wallenstein; A Schneider; M J Keller Journal: Osteoporos Int Date: 2007-12-11 Impact factor: 4.507
Authors: Kristin Mondy; Kevin Yarasheski; William G Powderly; Michael Whyte; Sherry Claxton; Debra DeMarco; Mary Hoffmann; Pablo Tebas Journal: Clin Infect Dis Date: 2003-01-29 Impact factor: 9.079
Authors: C Amiel; A Ostertag; L Slama; C Baudoin; T N'Guyen; E Lajeunie; L Neit-Ngeilh; W Rozenbaum; M C De Vernejoul Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741
Authors: E M Stein; M T Yin; D J McMahon; A Shu; C A Zhang; D C Ferris; I Colon; J F Dobkin; S M Hammer; E Shane Journal: Osteoporos Int Date: 2010-06-29 Impact factor: 4.507
Authors: Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann Journal: Proc Natl Acad Sci U S A Date: 2010-07-19 Impact factor: 11.205
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177